Announcements Trials
Browse Landscape

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Melanoma 69Leukemia, Myeloid, Acute 32Carcinoma, Renal Cell 27Neoplasm Metastasis 17Breast Neoplasms 16Leukemia 15Neuroblastoma 14Kidney Neoplasms 14Lymphoma, Non-Hodgkin 12Ovarian Neoplasms 11Carcinoma, Non-Small-Cell Lung 11Myelodysplastic Syndromes 10Recurrence 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Neoplasms 8Leukemia, Lymphocytic, Chronic, B-Cell 8Lymphoma 7Congenital Abnormalities 7Colorectal Neoplasms 7Leukemia, Myelogenous, Chronic, BCR-ABL Positive 6Skin Neoplasms 5Multiple Myeloma 5Lymphoma, Mantle-Cell 5Lymphoma, Follicular 5Head and Neck Neoplasms 5Fallopian Tube Neoplasms 5Carcinoma, Hepatocellular 5Rectal Neoplasms 4Mesothelioma, Malignant 4Lung Neoplasms 4

Interventions

Docetaxel 3Prednisone 2sargramostim 1epothilone B 1cabazitaxel 1Sunitinib 1PE regimen 1Interleukin-2 1Injections 1Everolimus 1Etoposide 1Cyclophosphamide 1Cisplatin 1Carboplatin 14-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Hormone Refractory Prostate Cancer × Interleukin-2 × Clear all
NCT02867345 2019-03-06

PD-1 Knockout Engineered T Cells for Castration Resistant Prostate Cancer

Peking University

Withdrawn
Genitourinary

Hormone Refractory Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡